NYSEAMERICAN:TRXC - TransEnterix Stock Price, Price Target & More

TransEnterix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "TRXC."

TransEnterix, Inc. (NYSEAMERICAN:TRXC) released its quarterly earnings data on Tuesday, May, 8th. The medical instruments supplier reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.07) by $0.01. The medical instruments supplier had revenue of $4.77 million for the quarter, compared to analyst estimates of $3.81 million. TransEnterix had a negative return on equity of 137.69% and a negative net margin of 21,045.36%. View TransEnterix's Earnings History.

3 brokerages have issued 1-year price targets for TransEnterix's stock. Their predictions range from $4.00 to $4.00. On average, they anticipate TransEnterix's share price to reach $4.00 in the next twelve months. View Analyst Ratings for TransEnterix.

TransEnterix saw a increase in short interest in the month of May. As of May 31st, there was short interest totalling 29,340,062 shares, an increase of 22.4% from the May 15th total of 23,962,795 shares. Based on an average daily trading volume, of 7,418,480 shares, the short-interest ratio is currently 4.0 days. Currently, 18.9% of the company's shares are short sold.

Some companies that are related to TransEnterix include Advanced Medical Solutions (AMS), CRH Medical (CRH), CRH Medical (CRHM), Tristel (TSTL), TSO3 (TOS), Clover (CLV), Bovie Medical (BVX), InfuSystem (INFU), Retractable Technologies (RVP), Milestone Scientific (MLSS), IsoRay (ISR), Akers Biosciences (AKR), Daxor (DXR), Omega Diagnostics Group (ODX) and Relevium Technologies (RLV).

Media headlines about TRXC stock have been trending positive this week, according to Accern Sentiment. The research firm identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. TransEnterix earned a media sentiment score of 0.34 on Accern's scale. They also assigned media stories about the medical instruments supplier an impact score of 43.35 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

TransEnterix's stock is owned by many different of retail and institutional investors. Top institutional investors include JPMorgan Chase & Co. (3.60%), Millennium Management LLC (0.94%), Royal Bank of Canada (0.58%), UBS Group AG (0.45%), Tibra Equities Europe Ltd (0.17%) and Element Capital Management LLC (0.10%). Company insiders that own TransEnterix stock include Andrea Biffi, Anthony C J Fernando, Joseph P Slattery, Richard C Pfenniger Jr, SPA Sofar, Todd Pope and Willam N Kelley. View Institutional Ownership Trends for TransEnterix.

TRXC stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, UBS Group AG, Tibra Equities Europe Ltd, Element Capital Management LLC, JPMorgan Chase & Co., Royal Bank of Canada and Barclays PLC. Company insiders that have bought TransEnterix stock in the last two years include Andrea Biffi, Richard C Pfenniger Jr, SPA Sofar and Willam N Kelley. View Insider Buying and Selling for TransEnterix.

Shares of TRXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of TRXC stock can currently be purchased for approximately $3.99.

TransEnterix has a market capitalization of $354.65 million.

TransEnterix's mailing address is 635 Davis Dr Ste 300, MORRISVILLE, NC 27560-7199, United States. The medical instruments supplier can be reached via phone at +1-919-7658400.